[1] |
LYNCH D A, SVERZELLATI N, TRAVIS W D,et al. Diagnostic criteria for idiopathic pulmonary fibrosis:a Fleischner Society White Paper[J]. Lancet Respir Med, 2018, 6(2):138-153. DOI: 10.1016/S2213-2600(17)30433-2.
|
[2] |
MAHER T M, BENDSTRUP E, DRON L,et al. Global incidence and prevalence of idiopathic pulmonary fibrosis[J]. Respir Res, 2021, 22(1):197. DOI: 10.1186/s12931-021-01791-z.
|
[3] |
COTTIN V, SCHMIDT A, CATELLA L,et al. Burden of idiopathic pulmonary fibrosis progression:a 5-year longitudinal follow-up study[J]. PLoS One, 2017, 12(1):e0166462. DOI: 10.1371/journal.pone.0166462.
|
[4] |
XUAN J W, LU Y J, REN M D,et al. Direct economic burden of idiopathic pulmonary fibrosis in China[J]. China Journal of Pharmaceutical Economics, 2019, 14(6):9-12. DOI: 10.12010/j.issn.1673-5846.2019.06.002.
|
[5] |
STRONGMAN H, KAUSAR I, MAHER T M. Incidence,prevalence,and survival of patients with idiopathic pulmonary fibrosis in the UK[J]. Adv Ther, 2018, 35(5):724-736. DOI: 10.1007/s12325-018-0693-1.
|
[6] |
|
[7] |
袁殷茹,张敏. 特发性肺纤维化预后相关生物标志物的研究进展[J]. 中国医药导报,2017,14(5):31-34.
|
[8] |
|
[9] |
ISHIKAWA N, HATTORI N, YOKOYAMA A,et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50(1):3-13. DOI: 10.1016/j.resinv.2012.02.001.
|
[10] |
SUN D, CHENG Z, JIANG T C,et al. Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF[J]. National Medical Journal of China, 2020, 100(10):748-752. DOI: 10.3760/cma.j.cn112137-20191008-02166.
|
[11] |
WAKAMATSU K, NAGATA N, KUMAZOE H,et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis[J]. Respir Investig, 2017, 55(1):16-23. DOI: 10.1016/j.resinv.2016.09.003.
|
[12] |
HUANG T H, KUO C W, CHEN C W,et al. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib:a retrospective real-world cohort study[J]. BMC Pulm Med, 2021, 21(1):165. DOI: 10.1186/s12890-021-01530-6.
|
[13] |
ALOISIO E, BRAGA F, PURICELLI C,et al. Prognostic role of Krebs von den Lungen-6(KL-6)measurement in idiopathic pulmonary fibrosis:a systematic review and meta-analysis[J]. Clin Chem Lab Med, 2021, 59(8):1400-1408. DOI: 10.1515/cclm-2021-0199.
|
[14] |
HAMAI K, IWAMOTO H, ISHIKAWA N,et al. Comparative study of circulating MMP-7,CCL18,KL-6,SP-A,and SP-D as disease markers of idiopathic pulmonary fibrosis[J]. Dis Markers, 2016, 2016:4759040. DOI: 10.1155/2016/4759040.
|
[15] |
D'ALESSANDRO M, BERGANTINI L, CAMELI P,et al. Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy[J]. Cancers(Basel), 2021, 13(4):689. DOI: 10.3390/cancers13040689.
|
[16] |
|
[17] |
GREENE K E, KING T E Jr, KUROKI Y,et al. Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2002, 19(3):439-446. DOI: 10.1183/09031936.02.00081102.
|
[18] |
WANG K, JU Q, CAO J,et al. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis:a systematic review and meta-analysis[J]. Medicine(Baltimore), 2017, 96(23):e7083. DOI: 10.1097/MD.0000000000007083.
|
[19] |
TAKAHASHI H, SHIRATORI M, KANAI A,et al. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D[J]. Respirology, 2006, 11(Suppl):S51-54. DOI: 10.1111/j.1440-1843.2006.00809.x.
|
[20] |
KINDER B W, BROWN K K, MCCORMACK F X,et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis[J]. Chest, 2009, 135(6):1557-1563. DOI: 10.1378/chest.08-2209.
|
[21] |
TODD J L, VINISKO R, LIU Y,et al. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort[J]. BMC Pulm Med, 2020, 20(1):64. DOI: 10.1186/s12890-020-1103-4.
|
[22] |
RICHARDS T J, KAMINSKI N, BARIBAUD F,et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2012, 185(1):67-76. DOI: 10.1164/rccm.201101-0058OC.
|
[23] |
SONG J W, DO K H, JANG S J,et al. Blood biomarkers MMP-7 and SP-A:predictors of outcome in idiopathic pulmonary fibrosis[J]. Chest, 2013, 143(5):1422-1429. DOI: 10.1378/chest.11-2735.
|
[24] |
TZOUVELEKIS A, HERAZO-MAYA J D, SLADE M,et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis[J]. Respirology, 2017, 22(3):486-493. DOI: 10.1111/resp.12920.
|
[25] |
BAUER Y, WHITE E S, DE BERNARD S,et al. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis[J]. ERJ Open Res, 2017, 3(1):00074-02016. DOI: 10.1183/23120541.00074-2016.
|
[26] |
SOKAI A, HANDA T, TANIZAWA K,et al. Matrix metalloproteinase-10:a novel biomarker for idiopathic pulmonary fibrosis[J]. Respir Res, 2015, 16:120. DOI: 10.1186/s12931-015-0280-9.
|
[27] |
LIAO Y, QI X L, CAO Y,et al. Elevations in the levels of NF-κB and inflammatory chemotactic factors in the brains with Alzheimer's disease - one mechanism may involve α3 nicotinic acetylcholine receptor[J]. Curr Alzheimer Res, 2016, 13(11):1290-1301. DOI: 10.2174/1567205013666160703174254.
|
[28] |
|
[29] |
XUE J M, KASS D J, BON J,et al. Plasma B lymphocyte Stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients[J]. J Immunol, 2013, 191(5):2089-2095. DOI: 10.4049/jimmunol.1203476.
|
[30] |
VUGA L J, TEDROW J R, PANDIT K V,et al. C-X-C motif chemokine 13(CXCL13)is a prognostic biomarker of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2014, 189(8):966-974. DOI: 10.1164/rccm.201309-1592OC.
|
[31] |
GUO L, YANG Y, LIU F,et al. Clinical research on prognostic evaluation of subjects with IPF by peripheral blood biomarkers,quantitative imaging characteristics and pulmonary function parameters[J]. Arch Bronconeumol(Engl Ed), 2020, 56(6):365-372. DOI: 10.1016/j.arbres.2019.08.020.
|
[32] |
PRASSE A, PROBST C, BARGAGLI E,et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2009, 179(8):717-723. DOI: 10.1164/rccm.200808-1201OC.
|
[33] |
JIA J, DEPIANTO D, ABBAS A R,et al. P022 Assessing the prognostic performance of CCL18,MMP7,YKL40 and periostin in bronchoalveolar lavage and peripheral blood in idiopathic pulmonary fibrosis[J]. QJM, 2016, 109(suppl_1):S29. DOI: 10.1093/qjmed/hcw119.026.
|
[34] |
CALISKAN C, JGER B, TERWOLBECK O,et al. Serum CCL18 levels predict survival and disease progression in IPF patients treated with antifibrotic drugs[J]. Pneumologie, 2019, 73(2):112-113. DOI: 10.1055/s-0039-1678394.
|
[35] |
NEIGHBORS M, CABANSKI C R, RAMALINGAM T R,et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone:post-hoc assessment of the CAPACITY and ASCEND trials[J]. Lancet Respir Med, 2018, 6(8):615-626. DOI: 10.1016/S2213-2600(18)30185-1.
|
[36] |
SIDEEK M A, SMITH J, MENZ C,et al. A central bioactive region of LTBP-2 stimulates the expression of TGF-β1 in fibroblasts via Akt and p38 signalling pathways[J]. Int J Mol Sci, 2017, 18(10):E2114. DOI: 10.3390/ijms18102114.
|
[37] |
SURI F, YAZDANI S, ELAHI E. LTBP2 knockdown and oxidative stress affect glaucoma features including TGFβ pathways,ECM genes expression and apoptosis in trabecular meshwork cells[J]. Gene, 2018, 673:70-81. DOI: 10.1016/j.gene.2018.06.038.
|
[38] |
ENOMOTO Y, MATSUSHIMA S, SHIBATA K,et al. LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis[J]. Clin Sci(Lond), 2018, 132(14):1565-1580. DOI: 10.1042/CS20180435.
|
[39] |
|
[40] |
|
[41] |
SATTAR Z, LORA A, JUNDI B,et al. The S100 protein family as players and therapeutic targets in pulmonary diseases[J]. Pulm Med, 2021, 2021:5488591. DOI: 10.1155/2021/5488591.
|
[42] |
LI Y N, BAO J, BIAN Y Y,et al. S100A4+ macrophages are necessary for pulmonary fibrosis by activating lung fibroblasts[J]. Front Immunol, 2018, 9:1776. DOI: 10.3389/fimmu.2018.01776.
|
[43] |
LEE J U, CHANG H S, SHIM E Y,et al. The S100 calcium-binding protein A4 level is elevated in the lungs of patients with idiopathic pulmonary fibrosis[J]. Respir Med, 2020, 171:105945. DOI: 10.1016/j.rmed.2020.105945.
|
[44] |
AKIYAMA N, HOZUMI H, ISAYAMA T,et al. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis[J]. Respirology, 2020, 25(7):743-749. DOI: 10.1111/resp.13707.
|
[45] |
HESSELSTRAND R, WILDT M, BOZOVIC G,et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis[J]. Respir Med, 2013, 107(7):1079-1086. DOI: 10.1016/j.rmed.2013.03.015.
|
[46] |
HARA A, SAKAMOTO N, ISHIMATSU Y,et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis[J]. Respir Med, 2012, 106(4):571-580. DOI: 10.1016/j.rmed.2011.12.010.
|
[47] |
BENNETT D, SALVINI M, FUI A,et al. Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP[J]. Inflammation, 2019, 42(2):463-470. DOI: 10.1007/s10753-018-00955-2.
|
[48] |
MACHAHUA C, GULER S A, HORN M P,et al. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis:a cross-sectional study in two independent cohorts[J]. BMJ Open Respir Res, 2021, 8(1):e000827. DOI: 10.1136/bmjresp-2020-000827.
|
[49] |
SHENDEROV K, COLLINS S L, POWELL J D,et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis[J]. J Clin Invest, 2021, 131(2):143226. DOI: 10.1172/JCI143226.
|
[50] |
LI Y P, HE Y W, CHEN S B,et al. S100A12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis[J]. Front Immunol, 2022, 13:810338. DOI: 10.3389/fimmu.2022.810338.
|
[51] |
LOMAS-NEIRA J, VENET F, CHUNG C S,et al. Neutrophil-endothelial interactions mediate angiopoietin-2-associated pulmonary endothelial cell dysfunction in indirect acute lung injury in mice[J]. Am J Respir Cell Mol Biol, 2014, 50(1):193-200. DOI: 10.1165/rcmb.2013-0148OC.
|
[52] |
UEHARA M, ENOMOTO N, MIKAMO M,et al. Impact of angiopoietin-1 and-2 on clinical course of idiopathic pulmonary fibrosis[J]. Respir Med, 2016, 114:18-26. DOI: 10.1016/j.rmed.2016.03.001.
|
[53] |
|
[54] |
HANCOCK L A, HENNESSY C E, SOLOMON G M,et al. Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice[J]. Nat Commun, 2018, 9(1):5363. DOI: 10.1038/s41467-018-07768-9.
|
[55] |
WANG H, ZHUANG Y, PENG H,et al. The relationship between MUC5B promoter,TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort[J]. Sci Rep, 2019, 9(1):15307. DOI: 10.1038/s41598-019-51902-6.
|
[56] |
|
[57] |
JIANG H M,HU Y J,SHANG L,et al. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis[J]. Int J Clin Exp Pathol,2015,8(11):14953-14958.
|
[58] |
|
[59] |
PELJTO A L, ZHANG Y Z, FINGERLIN T E,et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis[J]. JAMA, 2013, 309(21):2232-2239. DOI: 10.1001/jama.2013.5827.
|
[60] |
BIONDINI D, COCCONCELLI E, BERNARDINELLO N,et al. Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis(IPF)on antifibrotic treatment[J]. Respir Res, 2021, 22(1):98. DOI: 10.1186/s12931-021-01694-z.
|
[61] |
NOTH I, ZHANG Y Z, MA S F,et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality:a genome-wide association study[J]. Lancet Respir Med, 2013, 1(4):309-317. DOI: 10.1016/S2213-2600(13)70045-6.
|
[62] |
STERCLOVA M, KISHORE A, SIKOROVA K,et al. Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment[J]. Biomed Rep, 2021, 15(5):87. DOI: 10.3892/br.2021.1463.
|
[63] |
BONELLA F, CAMPO I, ZORZETTO M,et al. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms(SNPs)in the management of patients with IPF[J]. Orphanet J Rare Dis, 2021, 16(1):111. DOI: 10.1186/s13023-021-01750-3.
|
[64] |
MOLINA-MOLINA M, PLANAS-CEREZALES L, PERONA R. Telomere shortening in idiopathic pulmonary fibrosis[J]. Arch Bronconeumol(Engl Ed), 2018, 54(1):3-4. DOI: 10.1016/j.arbres.2017.07.026.
|
[65] |
CAIRNEY C J, KEITH W N. Telomerase redefined:integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity[J]. Biochimie, 2008, 90(1):13-23. DOI: 10.1016/j.biochi.2007.07.025.
|
[66] |
ARMANIOS M. Telomeres and age-related disease:how telomere biology informs clinical paradigms[J]. J Clin Invest, 2013, 123(3):996-1002. DOI: 10.1172/JCI66370.
|
[67] |
STUART B D, LEE J S, KOZLITINA J,et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis:an observational cohort study with independent validation[J]. Lancet Respir Med, 2014, 2(7):557-565. DOI: 10.1016/S2213-2600(14)70124-9.
|
[68] |
DAI J H, CAI H R, LI H,et al.Association between telomere length and survival in patients with idiopathic pulmonary fibrosis[J]. Respirology, 2015, 20(6):947-952. DOI: 10.1111/resp.12566.
|
[69] |
WANG H, ZHUANG Y, PENG H,et al. The relationship between MUC5B promoter,TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort[J]. Sci Rep, 2019, 9(1):15307. DOI: 10.1038/s41598-019-51902-6.
|
[70] |
SNETSELAAR R, VAN BATENBURG A A, VAN OOSTERHOUT M F M,et al. Short telomere length in IPF lung associates with fibrotic lesions and predicts survival[J]. PLoS One, 2017, 12(12):e0189467. DOI: 10.1371/journal.pone.0189467.
|
[71] |
ZHENG C M, ZHAN X, YANG Y H,et al. A rare missense variant in telomerase reverse transcriptase is associated with idiopathic pulmonary fibrosis in a Chinese Han family[J]. Chin Med J(Engl), 2018, 131(18):2205-2209. DOI: 10.4103/0366-6999.240802.
|
[72] |
ARMANIOS M Y, CHEN J J, COGAN J D,et al. Telomerase mutations in families with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2007, 356(13):1317-1326. DOI: 10.1056/NEJMoa066157.
|
[73] |
HAN M K, ZHOU Y R, MURRAY S,et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis:an analysis of the COMET study[J]. Lancet Respir Med, 2014, 2(7):548-556. DOI: 10.1016/S2213-2600(14)70069-4.
|
[74] |
|
[75] |
TAKAHASHI Y, SAITO A, CHIBA H,et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis[J]. Respir Res, 2018, 19(1):34. DOI: 10.1186/s12931-018-0736-9.
|
[76] |
MOLYNEAUX P L, WILLIS-OWEN S A G, COX M J,et al. Host-microbial interactions in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2017, 195(12):1640-1650. DOI: 10.1164/rccm.201607-1408OC.
|
[77] |
BUCALA R,SPIEGEL L A,CHESNEY J,et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair[J]. Mol Med,1994,1(1):71-81.
|
[78] |
QUAN T E, COWPER S E, BUCALA R. The role of circulating fibrocytes in fibrosis[J]. Curr Rheumatol Rep, 2006, 8(2):145-150. DOI: 10.1007/s11926-006-0055-x.
|
[79] |
HEUKELS P, VAN HULST J A C, VAN NIMWEGEN M,et al. Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis[J]. Respir Res, 2018, 19(1):90. DOI: 10.1186/s12931-018-0798-8.
|
[80] |
MOELLER A, GILPIN S E, ASK K,et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2009, 179(7):588-594. DOI: 10.1164/rccm.200810-1534OC.
|
[81] |
STEWART I D, NANJI H, FIGUEREDO G,et al. Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2021, 58(1):2100172. DOI: 10.1183/13993003.00172-2021.
|